Clinical activity after fingolimod cessation: disease reactivation or rebound?-Reference-Cited by-同舟云学术

Clinical activity after fingolimod cessation: disease reactivation or rebound?

Published:2018-07-10 Issue:10 Volume:25 Page:1270-1275
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Frau J.¹^ORCID,Sormani M. P.²,Signori A.²,Realmuto S.³,Baroncini D.⁴,Annovazzi P.⁴,Signoriello E.⁵,Maniscalco G. T.⁶,La Gioia S.⁷,Cordioli C.⁸,Frigeni B.⁷,Rasia S.⁸,Fenu G.¹,Grasso R.⁹,Sartori A.¹⁰,Lanzillo R.¹¹^ORCID,Stromillo M. L.¹²,Rossi S.¹³,Forci B.¹⁴,Cocco E.¹,

Affiliation:

1. Department of Medical Sciences and Public Health University of Cagliari CagliariItaly

2. Department of Health Sciences Section of Biostatistics University of Genova GenovaItaly

3. Department of Experimental Biomedicine and Clinical Neurosciences University of Palermo PalermoItaly

4. Multiple Sclerosis Study Centre AO s. Antonio Abate GallarateItaly

5. Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences Second University of Naples NaplesItaly

6. Neurological Clinic and Multiple Sclerosis Centre of ‘AORN A.Cardarelli’ NaplesItaly

7. USC Neurologia ASST Papa Giovanni XXIII BergamoItaly

8. Multiple Sclerosis Center Spedali Civili of Brescia Presidio di Montichiari BresciaItaly

9. Neurologia Universitaria OORR FoggiaItaly

10. Clinica Neurologica Azienda Ospedaliero‐Universitaria Ospedali Riuniti di Trieste TriesteItaly

11. Department of Neurosciences, Reproductive Sciences and Odontostomatology Multiple Sclerosis Centre Federico II University NaplesItaly

12. Department of Medicine, Surgery and Neuroscience University of Siena SienaItaly

13. Neuroimmunology and Neuromuscular Diseases Unit IRCCS Fondazione Istituto Neurologico Carlo Besta MilanoItaly

14. Dipartimento di Neuroscienze Azienda Ospedaliero‐Universitaria Careggi Area del farmaco e Salute del bambino (NEUROFARBA) Florence Italy

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.13694

Reference21 articles.

1. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

2. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

3. Rebound of Disease Activity After Withdrawal of Fingolimod (FTY720) Treatment

4. Withdrawal of fingolimod treatment for relapsing–remitting multiple sclerosis: report of six cases

5. Rebound exacerbation multiple sclerosis following cessation of oral treatment

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recurring disease activity in relapsing remitting multiple sclerosis: The multicenter RDA-RMS study;Multiple Sclerosis and Related Disorders;2024-08

2. Beyond conventional therapies: IVIG in treating severe fingolimod-rebound in a postpartum patient with MS;BMJ Case Reports;2024-07

3. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS;JAMA Neurology;2024-05-01

4. Frequency and risk factors of rebound after fingolimod discontinuation – A retrospective study;Multiple Sclerosis and Related Disorders;2024-01

5. Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice;International Immunopharmacology;2023-12